T cell targeting therapies – January 2021 T cell targeting therapies – January 2021 TScan Therapeutics announced $100 million Series C financing managed by BlackRock and RA Capital 25 Jan 2021 TScan Therapeutics – TSC-100 and TSC-101 (TCR-T cell therapy) […]
T cell targeting therapies – January 2021 T cell targeting therapies – January 2021 Kuur Therapeutics reported interim clinical data that supports the CAR-NKT cell therapy platform 21 Jan 2020 Kuur Therapeutics – KUR-501 (autologous GD2 CAR-NKT cells)/ KUR-502 (off-the-shelf […]
T cell targeting therapies – January 2021 T cell targeting therapies – January 2021 Harpoon Therapeutics received Orphan Drug Designation from FDA for HPN217 for treatment of multiple myeloma 13 Jan 2021 Harpoon Therapeutics – HPN217 (Anti-BCMA Tri specific T-cell […]
T cell targeting therapies – January 2021 T cell targeting therapies – January 2021 Janux Therapeutics announced a collaboration with Merck to develop novel drug candidates for immuno-oncology using T cell engager (TRACTr) technology 18 Dec 2020 Janux Therapeutics/Merck – […]
